|Trade names||IsonaRif, Rifamate, others|
|Defined daily dose||not established|
Isoniazid/rifampicin, also known as isoniazid/rifampin, is a medication used to treat tuberculosis. It is a fixed dose combination of isoniazid and rifampicin (rifampin). It is used together with other antituberculosis medication. It is taken by mouth.
Side effects are those of the underlying medications. Common side effects include poor coordination, poor appetite, nausea, numbness, and feeling tired. More severe side effects include liver problems. Use is generally not recommended in children. It is unclear if use is safe in pregnancy.
It is on the World Health Organization's List of Essential Medicines. The wholesale cost in the developing world is about US$5.10 a month. In the United Kingdom a month of medication costs the NHS about 28.11 pounds.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 18 September 2020. CS1 maint: discouraged parameter (link)
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 142. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016. CS1 maint: discouraged parameter (link)
- "Isoniazid/rifampin Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016. CS1 maint: discouraged parameter (link)
- "Isoniazid / rifampin Use During Pregnancy | Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016. CS1 maint: discouraged parameter (link)
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Rifampicin + Isoniazid". International Drug Price Indicator Guide. Retrieved 8 December 2016. CS1 maint: discouraged parameter (link)
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 403. ISBN 9780857111562.